At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, delivered a talk on “The Current State of Renal Oncology in Turkey”.
At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, delivered an in-depth presentation on “The Current State of Renal Oncology in Turkey.”
He outlined the national epidemiology of kidney cancer, noting its incidence, male-to-female ratio, and earlier age at diagnosis compared with the United States. Drawing from the Turkish Kidney Cancer Consortium (TKCC) registry, which includes more than 2,000 metastatic RCC patients across 15 centers, Dr. Yekedüz reported that survival outcomes are broadly aligned with international benchmarks, with median overall survival exceeding 40 months in favorable-risk groups. He also discussed treatment attrition, highlighting that only 60% of patients receive second-line therapy, and underscored the role of toxicity in discontinuations.
Subtype-specific outcomes, particularly poorer results in papillary RCC, were detailed based on Turkish registry data and comparisons with global series. Finally, Dr. Yekedüz stressed the importance of expanding clinical trial participation, advancing molecular stratification, and fostering international collaborations to accelerate translational research and innovation in renal oncology.
Join us in this conversation.